Biotech Values

[rkrw]

178 and 249 came from Sandoz originally. I'd guess the royalties are single digit, not 50/50, but who knows since they wont say.

On fragmin, I guess you missed my point in that it will never be developed. Not commercially attractive.

this is from the mnta 10K:

<<<The M-Dalteparin program has been reprioritized in light of other more commercially attractive opportunities.>>>